Payne Cathy, Wiffen Philip J, Martin Suzanne
All Ireland Institute of Hospice and Palliative Care, School of Health Sciences, University of Ulster, Belfast, Northern Ireland, UK.
Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield Division of Anaesthetics), University of Oxford, Pain Research Unit, Churchill Hospital, Oxford, Oxfordshire, UK, OX3 7LE.
Cochrane Database Syst Rev. 2017 Apr 7;4(4):CD008427. doi: 10.1002/14651858.CD008427.pub3.
Fatigue and unintentional weight loss are two of the commonest symptoms experienced by people with advanced progressive illness. Appropriate interventions may bring considerable improvements in function and quality of life to seriously ill people and their families, reducing physical, psychological and spiritual distress.
To conduct an overview of the evidence available on the efficacy of interventions used in the management of fatigue and/or unintentional weight loss in adults with advanced progressive illness by reviewing the evidence contained within Cochrane reviews.
We searched the Cochrane Database of Systematic Reviews (CDSR) for all systematic reviews evaluating any interventions for the management of fatigue and/or unintentional weight loss in adults with advanced progressive illness (The Cochrane Library 2010, Issue 8). We reviewed titles of interest by abstract. Where the relevance of a review remained unclear we reached a consensus regarding the relevance of the participant group and the outcome measures to the overview. Two overview authors extracted the data independently using a data extraction form. We used the measurement tool AMSTAR (Assessment of Multiple SysTemAtic Reviews) to assess the methodological quality of each systematic review.
We included 27 systematic reviews (302 studies with 31,833 participants) in the overview. None of the included systematic reviews reported quantitative data on the efficacy of interventions to manage fatigue or weight loss specific to people with advanced progressive illness. All of the included reviews apart from one were deemed of high methodological quality. For the remaining review we were unable to ascertain the methodological quality of the research strategy as it was described. None of the systematic reviews adequately described whether conflict of interests were present within the included studies. Management of fatigueAmyotrophic lateral sclerosis/motor neuron disease (ALS/MND) - we identified one systematic review (two studies and 52 participants); the intervention was exercise.Cancer - we identified five systematic reviews (116 studies with 17,342 participants); the pharmacological interventions were eicosapentaenoic acid (EPA) and any drug therapy for the management of cancer-related fatigue and the non pharmacological interventions were exercise, interventions by breast care nurses and psychosocial interventions.Chronic obstructive pulmonary disease (COPD) - we identified three systematic reviews (59 studies and 4048 participants); the interventions were self management education programmes, nutritional support and pulmonary rehabilitation.Cystic fibrosis - we identified one systematic review (nine studies and 833 participants); the intervention was physical training.Human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) - we identified two systematic reviews (21 studies and 748 participants); the interventions were progressive resistive exercise and aerobic exercise.Multiple sclerosis (MS) - we identified five systematic reviews (23 studies and 1502 participants); the pharmacological interventions were amantadine and carnitine. The non pharmacological interventions were diet, exercise and occupational therapy.Mixed conditions in advanced stages of illness - we identified one systematic review (five studies and 453 participants); the intervention was medically assisted hydration. Management of weight lossALS/MND - we identified one systematic review but no studies met the inclusion criteria for the systematic review; the intervention was enteral tube feeding.Cancer - we identified three systematic reviews with a fourth systematic review also containing extractable data on cancer (66 studies and 5601 participants); the pharmacological interventions were megestrol acetate and eicosapentaenoic acid (EPA) (this systematic review is also included in the cancer fatigue section above). The non pharmacological interventions were enteral tube feeding and non invasive interventions for patients with lung cancer.COPD - we identified one systematic review (59 studies and 4048 participants); the intervention was nutritional support. This systematic review is also included in the COPD fatigue section.Cystic fibrosis - we identified two systematic reviews (three studies and 131 participants); the interventions were enteral tube feeding and oral calorie supplements.HIV/AIDS - we identified four systematic reviews (42 studies and 2071 participants); the pharmacological intervention was anabolic steroids. The non pharmacological interventions were nutritional interventions, progressive resistive exercise and aerobic exercise. Both of the systematic reviews on exercise interventions were also included in the HIV/AIDS fatigue section.MS - we found no systematic reviews which considered interventions to manage unintentional weight loss for people with a clinical diagnosis of multiple sclerosis at any stage of illness.Mixed conditions in advanced stages of illness - we identified two systematic reviews (32 studies and 4826 participants); the interventions were megestrol acetate and medically assisted nutrition.
AUTHORS' CONCLUSIONS: There is a lack of robust evidence for interventions to manage fatigue and/or unintentional weight loss in the advanced stage of progressive illnesses such as advanced cancer, heart failure, lung failure, cystic fibrosis, multiple sclerosis, motor neuron disease, Parkinson's disease, dementia and AIDS. The evidence contained within this overview provides some insight into interventions which may prove of benefit within this population such as exercise, some pharmacological treatments and support for self management.Researchers could improve the methodological quality of future studies by blinding of outcome assessors. Adopting uniform reporting mechanisms for fatigue and weight loss outcome measures would also allow the opportunity for meta-analysis of small studies.Researchers could also improve the applicability of recommendations for interventions to manage fatigue and unintentional weight loss in advanced progressive illness by including subgroup analysis of this population within systematic reviews of applicable interventions.More research is required to ascertain the best interventions to manage fatigue and/or weight loss in advanced illness. There is a need for standardised reporting of these symptoms and agreement amongst researchers of the minimum duration of studies and minimum percentage change in symptom experience that proves the benefits of an intervention. There are, however, challenges in providing meaningful outcome measurements against a background of deteriorating health through disease progression. Interventions to manage these symptoms must also be mindful of the impact on quality of life and should be focused on patient-orientated rather than purely disease-orientated experiences for patients. Systematic reviews and primary intervention studies should include the impact of the interventions on standardised validated quality of life measures.
疲劳和非故意性体重减轻是晚期进行性疾病患者最常见的两种症状。适当的干预措施可能会给重症患者及其家人的功能和生活质量带来显著改善,减轻身体、心理和精神痛苦。
通过回顾Cochrane系统评价中的证据,对用于管理晚期进行性疾病成人疲劳和/或非故意性体重减轻的干预措施的疗效证据进行概述。
我们在Cochrane系统评价数据库(CDSR)中检索了所有评估用于管理晚期进行性疾病成人疲劳和/或非故意性体重减轻的任何干预措施的系统评价(《Cochrane图书馆》2010年第8期)。我们通过摘要审查感兴趣的标题。如果某一系统评价的相关性仍不明确,我们就该参与人群和结局指标与概述的相关性达成共识。两位概述作者使用数据提取表独立提取数据。我们使用测量工具AMSTAR(多系统评价评估)来评估每个系统评价的方法学质量。
我们在概述中纳入了27项系统评价(302项研究,31833名参与者)。纳入的系统评价均未报告针对晚期进行性疾病患者管理疲劳或体重减轻的干预措施疗效的定量数据。除一项外,所有纳入的系统评价均被认为方法学质量高。对于其余的系统评价,由于其描述方式,我们无法确定研究策略的方法学质量。没有系统评价充分描述纳入研究中是否存在利益冲突。
疲劳管理
肌萎缩侧索硬化症/运动神经元病(ALS/MND)——我们确定了一项系统评价(两项研究,52名参与者);干预措施为运动。
癌症——我们确定了五项系统评价(116项研究,17342名参与者);药物干预措施为二十碳五烯酸(EPA)和用于管理癌症相关疲劳的任何药物治疗,非药物干预措施为运动、乳腺护理护士的干预和心理社会干预。
慢性阻塞性肺疾病(COPD)——我们确定了三项系统评价(59项研究,4048名参与者);干预措施为自我管理教育项目、营养支持和肺康复。
囊性纤维化——我们确定了一项系统评价(九项研究,833名参与者);干预措施为体育训练。
人类免疫缺陷病毒/获得性免疫缺陷综合征(HIV/AIDS)——我们确定了两项系统评价(21项研究,748名参与者);干预措施为渐进性抗阻运动和有氧运动。
多发性硬化症(MS)——我们确定了五项系统评价(23项研究,1502名参与者);药物干预措施为金刚烷胺和肉碱。非药物干预措施为饮食、运动和职业治疗。
晚期疾病的混合情况——我们确定了一项系统评价(五项研究,453名参与者);干预措施为医学辅助补液。
体重减轻管理
ALS/MND——我们确定了一项系统评价,但没有研究符合该系统评价的纳入标准;干预措施为肠内管饲。
癌症——我们确定了三项系统评价,第四项系统评价也包含关于癌症的可提取数据(66项研究,5601名参与者);药物干预措施为醋酸甲地孕酮和二十碳五烯酸(EPA)(该系统评价也包含在上述癌症疲劳部分)。非药物干预措施为肠内管饲和针对肺癌患者 的非侵入性干预。
COPD——我们确定了一项系统评价(59项研究,4048名参与者);干预措施为营养支持。该系统评价也包含在COPD疲劳部分。
囊性纤维化——我们确定了两项系统评价(三项研究,131名参与者);干预措施为肠内管饲和口服热量补充剂。
HIV/AIDS——我们确定了四项系统评价(42项研究,2071名参与者);药物干预措施为合成代谢类固醇。非药物干预措施为营养干预、渐进性抗阻运动和有氧运动。关于运动干预的两项系统评价也包含在HIV/AIDS疲劳部分。
MS——我们未发现考虑在疾病任何阶段对临床诊断为多发性硬化症患者管理非故意性体重减轻的干预措施的系统评价。
晚期疾病的混合情况——我们确定了两项系统评价(32项研究,4826名参与者);干预措施为醋酸甲地孕酮和医学辅助营养。
对于晚期进行性疾病如晚期癌症、心力衰竭、肺衰竭、囊性纤维化、多发性硬化症、运动神经元病、帕金森病、痴呆症和艾滋病患者管理疲劳和/或非故意性体重减轻的干预措施,缺乏有力证据。本概述中的证据为一些可能对该人群有益的干预措施提供了一些见解,如运动、一些药物治疗和自我管理支持。
研究人员可通过对结局评估者进行盲法来提高未来研究的方法学质量。采用统一的疲劳和体重减轻结局指标报告机制也将为小研究进行荟萃分析提供机会。
研究人员还可通过在适用干预措施的系统评价中纳入该人群的亚组分析,提高晚期进行性疾病患者管理疲劳和非故意性体重减轻干预措施建议的适用性。
需要更多研究来确定晚期疾病管理疲劳和/或体重减轻的最佳干预措施。需要对这些症状进行标准化报告,研究人员之间需要就证明干预措施益处的研究最短持续时间和症状体验的最小百分比变化达成一致。然而,在疾病进展导致健康状况恶化的背景下提供有意义的结局测量存在挑战。管理这些症状的干预措施还必须考虑对生活质量的影响,应关注以患者为导向而非纯粹以疾病为导向的患者体验。系统评价和原发性干预研究应包括干预措施对标准化验证的生活质量测量的影响。